Tuesday , 22 October 2019

Aurora Cannabis (NYSE:ACB) vs. Canopy Growth (NYSE:CGC): Which Stock is Better?

As cannabis continues to become an increasingly significant sector, investors will want to know whether Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB) or Canopy Growth Corporation (TSX:WEED) (NYSE:CGC) is expected to become the dominate market leader so, in this article, smallcappower.com compares both companies’ performances over the past few quarters.

Revenue Growth

Canopy Growth Corporation announced financial results for Q1/20 (ended June 30, 2019) on August 14, 2019. Revenue was well below analyst expectations and the stock has fallen by more than 18% since. Aurora Cannabis, meanwhile, is expected to report Q4/19 (ended June 30, 2019) financial results on September 11, 2019, after markets close. Management has provided revenue guidance of between $100M to $107M for the quarter.

Figure 1: Net Revenues: Canopy Growth vs Aurora Cannabis (M $CAD)

Source: Company Reports, Ubika

Note /1: Midpoint of Aurora Management Revenue Guidance for Q4/19, $100M-$107M

Figure 2: Canopy Growth Summary of Quarterly Financial Results (M $CAD)

Source: Company Reports, Ubika

Figure 3: Aurora Cannabis Summary of Quarterly Financial Results (M $CAD)

Source: Company Reports, Ubika Research

Canopy Growth is poised to become a dominate player globally, but its revenues have remained sticky over the past three quarters as more cultivation has been coming online. Canopy Growth’s revenue decreased by 3.8% QoQ to $90.5M, while recreational revenue was down ~$8M compared with the previous quarter, but this was offset by an ~9M increase in international medical sales (Figure 2). This increase in international revenue was due primarily to its acquisition of German-based C3 Cannabinoid Compound Company, which sells full-spectrum, cannabidiol-based medicines in Germany.

Aurora Cannabis Inc’s management has provided guidance for a 59% sequential increase in revenue, which implies a compound annual growth rate (CAGR) of 45% over the past six quarters. The Company expects Q4/19 net revenue to be between $100M to $107M, with net cannabis revenue of between $90M – $95M. Of note, cannabis revenue in this range would be the highest reported so far by any Canadian cultivator. Aurora’s Q3/19 results are highlighted by international revenue of $4.0M. Recreational revenues have been increasing sequentially since the legalization of the adult-use market in Canada. In addition, Aurora Cannabis expects to produce between 25,000 and 30,000 kg of cannabis during the fourth quarter.

Canopy Growth’s recreational sales have been poor over the past three quarters, with recreational revenue down 15% since Q3/18. Additionally, Canopy Growth Corp’s Canadian medical sales have slid ~35% over the past three quarters, while Aurora Cannabis Inc’s have increase by ~30% during the same time frame. We believe that Canopy Growth likely has lost its position as cannabis market leader, with Aurora gaining some of Canopy’s market share.

Figure 4: Cannabis Cultivation (kg): Canopy vs Aurora

Source: Company Reports, Ubika

Cannabis Cultivation

Until the last few quarters, Canopy Growth had a considerable lead over Aurora Cannabis in cultivation, however Aurora has begun to close the gap and now both companies produce similar quantities of cannabis (Figure 4). For the quarter ended June 30, 3019, Canopy harvested 40,000 kg of cannabis while Aurora expects to harvest between 25,000 to 30,000. There likely will be an oversupply of cannabis within the next two years as the 21.8M sq. ft (Financial Post) of cultivation space comes online. As such, kilograms sold is going to become a more meaningful metric than cannabis harvested.

Figure 5: Gross Margins ex-FV adjustments: Canopy Growth vs. Aurora Cannabis

Source: Company Reports, Ubika

Gross margins before fair value adjustments

Probably the most striking contrast between Canopy Growth and Aurora Cannabis is the discrepancy in gross margins between the two cultivators. Canopy Growth’s gross margin contracted by 130 bps to 14.6% for Q1/20 (ended June 30, 2019), while Aurora’s gross margins expanded by 330 bps over the last two quarter in which data is currently available. During Canopy’s earnings call, CFO Mike Lee mentioned that the lower gross margin was due primarily to $16.2M of expenses for facilities not yet cultivating or processing cannabis or facilities that has underutilized capacity. There have also been rumours of crop failures, particularly at Canopy’s BC Tweed facility, which could be contributing to higher costs for the Company, although Canopy Growth is not likely to admit it. Aurora’s gross margins are the second best in the sector (behind Organigram), compared with Canopy, which are some of worse.

Profitability

During Canopy Growth Corp’s last earnings call, CFO Mike Lee mentioned that it could be three to five years before the Company becomes profitable. Aurora Cannabis, however, is expected to become profitable within FY2020. As both companies are establishing global operations the path to profitability is long, however Aurora takes the lead here as it could become profitable two to four years before Canopy.

Goodwill and Intangible Assets

As of June 30, 2019, Canopy Growth had ~$2.5B in goodwill and intangibles on its balance sheet, and as of March 31, 2019, Aurora had ~$3.9B in goodwill and intangibles. Canopy paid $270M for Tokyo Smoke and its seven coffee shops, while Aurora Cannabis paid $3.2B to acquire MedReleaf, $1.1B to acquire CanniMed, and $290M to acquire ICC labs. With all these transactions a majority of the cost was allocated as goodwill. These assets were acquired at rich valuations and if it turns out that either Canopy or Aurora overpaid for these assets, the goodwill could be at risk of impairment for both companies. Goodwill and intangibles are tested for impairment annually by auditors and the auditors could require additional write-downs in order to sign off on financial statements in the future.

Conclusion

Both companies are definitely going to become global players and are poised to benefit from the legalization of Cannabis 2.0 in Canada coming this fall. If there is an edge, though, we would give it to Aurora Cannabis, as the Company has likely taken the position of market leader away from Canopy Growth, has a stronger medical business, has production on par with Canopy, and has a better gross margin.

Editor’s Note: The above excerpts from the original article by SmallCapPower.com have been edited ([ ]) and abridged (…) for the sake of clarity and brevity. Also note that this complete paragraph must be included in any re-posting to avoid copyright infringement.

Scroll to very bottom of page & add your comments on this article. We want to share what you have to say!

(The author’s views and conclusions are unaltered and no personal comments have been included to maintain the integrity of the original article. Furthermore, the views, conclusions and any recommendations offered in this article are not to be construed as an endorsement of such by the editor.)

Leave a Reply

Your email address will not be published. Required fields are marked *